Hepatocellular Carcinoma
| Editors: | Shuyou Peng, Ghassan K. Abou-Alfa, Patrick Pessaux |
Publisher: AME Publishing Company; 1st edition (2017)
ISBN-13: 978-9887784005
Hardcover: 423 pages
Language: English
Available at: 
It was not long ago that the incidence rate of hepatocellular carcinoma (HCC) approximated the mortality rate. Due to the causative relationship between chronic viral infection, chronic inflammation, hepatotoxins, and hepatocellular carcinoma, this cancer is responsible for nearly one million deaths yearly worldwide. The last years have seen tremendous progress in diagnosis and treatment of this common cancer. The current book edited by Professor Xiujun Cai comprehensively summarizes the current understanding of this disease within the context of patient treatment and outcome.
Honorary Editors
| Yuman Fong | Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA |
| J. Michael Millis | Department of Transplantation, University of Chicago, Chicago, IL 60637, USA |
| Massimo Colombo | Dipartimento di Medicina e Specialità Mediche, Divisione di Gastroenterologia 1, Centro AM e A Migliavacca per lo Studio delle Malattie del Fegato, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico e Università degli Studi di Milano, Italy |
Editors
| Shuyou Peng | Department of General Surgery, The second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou, China |
| Ghassan K. Abou-Alfa | Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA |
| Patrick Pessaux | Pôle Hépatodigestif, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France |
Associate Editors
| Gaetano Bertino | Hepatology Unit, Department of Medical and Pediatric Sciences - University of Catania, Catania, Italy |
| Zhixiang Jian | Guangdong General Hospital, Guangzhou, China |
| Lianxin Liu | The First Af liated Hospital of Harbin Medical University, Harbin, China |
| LunXiu Qin | Huashan Hospital, Fudan University, Shanghai, China |
| ChengYi Sun | The Af liated Hospital of GuiZhou Medical University, Guiyang, China |
| Kaishan Tao | Xijing Hospital, The Fourth Military Medical University, Xi'an, China |
| Zhanyu Yang | The General Hospital of People’s Liberation Army (301 Hospital) Beijing, China |
Table of Contents
Preface
Overview of Hepatocellular Carcinoma
1 Hepatocellular carcinoma: present and future
6 Hepatocellular carcinoma: expanding the horizon
9 Guidelines for the management of hepatocellular carcinoma: still in need of standardization
11 New insights in hepatocellular carcinoma: from bench to bedside
22 Hepatocellular carcinoma in the modern era: transplantation, ablation, open surgery or minimally invasive surgery? —A multidisciplinary personalized decision
32 Management of hepatocellular carcinoma should consider both tumor factors and background liver factors
37 A bridge between multi-omics data and the management of hepatocellular carcinoma
39 A review of hepatocellular carcinoma (HCC) staging systems
Current Status of Hepatocellular Carcinoma in Different Countries and Regions
51 Features and treatment options of Chinese hepatocellular carcinoma
57 Status of hepatocellular carcinoma in Republic of Korea
65 Current status of hepatocellular carcinoma in Japan
75 Hepatocellular carcinoma in India
80 Status of hepatocellular carcinoma in Gulf region
86 Risk factors for developing hepatocellular carcinoma in Egypt
95 Status of hepatocellular cancer in Europe
105 Current status of hepatocellular carcinoma in the United States
Basic Research of Hepatocellular Carcinoma
112 Pro ling HBV integrations in hepatocellular carcinoma cancer
115 Cellular and molecular mechanisms of hepatic brogenesis leading to liver cancer
122 Alcoholic liver disease - Hepatocellular carcinoma transformation
130 Viral hepatitis, non-alcoholic fatty liver disease and alcohol as risk factors for hepatocellular carcinoma
142 Vitamin E in prevention against hepatocellular carcinoma: right type, right dose and right population
146 Nutrition and metabolism in hepatocellular carcinoma
154 Multifocal hepatocellular carcinoma: intrahepatic metastasis or multicentric carcinogenesis?
159 Statins: emerging role in chemoprevention for hepatocellular carcinoma?
Potential Diagnostic Molecular Markers of Hepatocellular Carcinoma
163 Hepatocellular carcinoma: the rising tide from east to west—a review of epidemiology, screening and tumor markers
178 Novel biomarkers for hepatocellular carcinoma surveillance: has the future arrived?
183 DKK1 as a serum biomarker for hepatocellular carcinoma
185 Midkine as a new diagnostic tool in hepatocellular carcinoma
188 TIE2-expressing monocytes as a diagnostic marker for hepatocellular carcinoma correlates with angiogenesis
190 Serum biomarkers for early diagnosis of hepatocellular carcinoma
Surgical Resection and Transplantation for Hepatocellular Carcinoma
194 Surgical resection for hepatocellular carcinoma
204 Laparoscopic liver resection: basic skills for peripheral lesions
207 Laparoscopic resection for hepatocellular carcinoma: comparison between Middle Eastern and Western experience
220 Laparoscopic resection for hepatocellular carcinoma: eastern and western experiences
223 Robotic liver surgery
230 Liver transplantation for hepatocellular carcinoma
239 Review on liver transplant for hepatocellular carcinoma
249 Selection of patients of hepatocellular carcinoma beyond the Milan criteria for liver transplantation
254 Liver transplantation for hepatocellular carcinoma: are international guidelines possible?
Ablative Therapy for Hepatocellular Carcinoma
258 Percutaneous therapies of hepatocellular carcinoma—an update
269 High-intensity focused ultrasound (HIFU) for the treatment of hepatocellular carcinoma: is it time to abandon standard ablative percutaneous treatments?
273 Comparison of high-intensity focused ultrasound therapy and radiofrequency ablation for recurrent hepatocellular carcinoma
Radiation, Chemical and Targeted Therapies for Hepatocellular Carcinoma
276 Stereotactic body radiation therapy for primary hepatic malignancies and metastases to liver: a technical and literature review
290 C-arm dual-phase cone-beam CT: a revolutionary real-time imaging modality to assess drug-eluting beads TACE success in liver cancer patients
294 Proton therapy for hepatocellular carcinoma
301 Systemic therapy for hepatocellular carcinoma
315 Beyond chemotherapy: systemic treatment options for hepatocellular carcinoma
325 Current status of bevacizumab for advanced hepatocellular carcinoma
329 Ef cacy of combination treatment modalities for intermediate and advanced hepatocellular carcinoma: intra-arterial therapies, sorafenib and novel small molecules
341 Transcatheter embolization therapy in liver cancer: an update of clinical evidences
367 Management of liver cirrhosis in patients with hepatocellular carcinoma
Prognosis of HCC and Surgical Complications
386 Quality of life and hepatocellular carcinoma
408 Prediction of postoperative liver failure in patients diagnosed with hepatocellular carcinoma using 99mTc-GSA SPECT/CT
411 Post-hepatectomy liver failure
420 Importance of tumor/stroma interactions in prognosis of hepatocellular carcinoma
Click the book to view the entire PDF
